Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments

Aquatic Toxicology

Volumn 151, Issue , 2014, Pages 105-113

  Connors, Kristin A ^a   Valenti, Theodore W ^a,b   Lawless, Kelly ^c   Sackerman, James ^c   Onaivi, Emmanuel S ^c   Brooks, Bryan W ^a   Gould, Georgianna G ^d  

^a BAYLOR UNIVERSITY   (United States)

^b SYNGENTA CROP PROTECTION   (United States)

^c WILLIAM PATERSON UNIVERSITY   (United States)

^d University of Texas Health Science Center   (United States)

Author keywords

Anxiety; Aquatic exposure; Autoradiography; Cannabinoid; G i o coupled receptors; Inhibition; Light dark preference; Scototaxis; Serotonin

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; BRAIN PROTEIN; BUSPIRONE; CANNABINOID RECEPTOR; SEROTONIN 1A RECEPTOR;

BIOACCUMULATION; DRUG; ECOTOXICOLOGY; ENVIRONMENTAL RISK; FISH; INHIBITOR; RISK ASSESSMENT;

ADULT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; AUTORADIOGRAPHY; BINDING SITE; BRAIN REGION; BRAIN TISSUE; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENVIRONMENTAL FACTOR; HYPOTHALAMUS; LIGHT DARK CYCLE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SUPERIOR COLLICULUS; TELENCEPHALON; ZEBRA FISH;

DANIO RERIO; MAMMALIA;

ANXIETY; AQUATIC EXPOSURE; AUTORADIOGRAPHY; CANNABINOID; GΑI/O COUPLED RECEPTORS; INHIBITION; LIGHT/DARK PREFERENCE; SCOTOTAXIS; SEROTONIN;

ANIMALS; BEHAVIOR, ANIMAL; PROTEIN BINDING; RECEPTORS, CANNABINOID; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS; WATER POLLUTANTS, CHEMICAL; ZEBRAFISH;

EID: 84899493174     PISSN: 0166445X     EISSN: 18791514     Source Type: Journal    
DOI: 10.1016/j.aquatox.2013.12.005     Document Type: Article

References (93)

1. Airhart M.J., Lee D.H., Wilson T.D., Miller B.E., Miller M.N., Skalko R.G. Movement disorders and neurochemical changes in zebrafish larvae after bath exposure to fluoxetine (PROZAC). Neurotoxicol. Teratol. 2007, 29:652-664.
2. Airhart M.J., Lee D.H., Wilson T.D., Miller B.E., Miller M.N., Skalko R.G., Monaco J. Adverse effects of serotonin depletion in developing zebrafish. Neurotoxicol. Teratol. 2012, 34:152-160.
3. Akinshola B.E., Chakrabarti A., Onaivi E.S. In-vitro and in-vivo action of cannabinoids. Neurochem. Res. 1999, 24:1233-1240.
4. Ankley G.T., Bennett R.S., Erickson R.J., Hoff D.J., Hornugn M.W., Johnson R.D., Mount D.R., Nichols J.W., Russom C.L., Schmieder P.K., Serrano J.A., Tietge J.E., Villeneuve D.L. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 2010, 29:730-741.
5. Ashby C.R., Kehne J.H., Bartoszyk G.D., Renda M.J., Athanasiou M., Pierz K.A., Seyfried C.A. Electrophysiological evidence for rapid 5-HT(1A) autoreceptor inhibition by vilazodone, a 5-HT(1A) receptor partial agonist and 5-HT reuptake inhibitor. Eur. J. Pharmacol. 2013, 714:359-365.
6. Ashton J. Pro-drugs for indirect cannabinoids as therapeutic agents. Curr. Drug Deliv. 2008, 5:243-247.
7. Barba-Escobedo P.A., Gould G.G. Visual social preferences of lone zebrafish in a novel environment: strain and anxiolytic effects. Genes Brain Behav. 2012, 11:366-373.
8. Bencan Z., Sledge D., Levin E.D. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. Pharmacol. Biochem. Behav. 2009, 94:75-80.
9. Berninger J.P., Brooks B.W. Leveraging mammalian pharmaceutical toxicology and pharmacology data to predict chronic fish responses to pharmaceuticals. Toxicol. Lett. 2010, 193:69-78.
10. Boehmler W., Carr T., Thisse C., Thisse B., Canfield V.A., Levenson R. D4 dopamine receptor genes of zebrafish and effects of the antipsychotic clozapine on larval swimming behaviour. Genes Brain Behav. 2007, 6:155-166.
11. Boehmler W., Petko J., Woll M., Frey C., Thisse B., Thisse C., Canfield V.A., Levenson R. Identification of zebrafish A2 adenosine receptors and expression in developing embryos. Gene Expr. Patterns 2009, 9:144-151.
12. Boxall A.B.A., Rudd M., Brooks B.W., Caldwell D., Choi K., Hickmann S., Innes E., Ostapyk K., Staveley J., Verslycke T., Ankley G.T., Beazley K., Belanger S., Berninger J.P., Carriquiriborde P., Coors A., DeLeo P., Dyer S., Ericson J., Gagne F., Giesy J.P., Gouin T., Hallstrom L., Karlsson M., Larsson D.G.J., Lazorchak J., Mastrococco F., McLaughlin A., McMaster M., Meyerhoff R., Moore R., Parrott J., Snape J., Murray-Smith R., Servos M., Sibley P.K., Straub J.O., Szabo N., Tetrault G., Topp E., Trudeau V.L., van der Kraak G. Pharmaceuticals and personal care products in the environment: what are the big questions?. Environ. Health Perspect. 2012, 120:1221-1229.
13. Braida D., Limonta V., Pegorini S., Zani A., Guerini-Rocco C., Gori E., Sala M. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacology (Berl.) 2007, 190:441-448.
14. Breivogel C.S., Sim L.J., Childers S.R. Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 1997, 282:1632-1642.
15. Brooks B.W., Chambliss C.K., Stanley J.K., Ramirez A., Banks K.E., Johnson R.D., Russell J.L. Determination of select antidepressants in fish from an effluent-dominated stream. Environ. Toxicol. Chem. 2005, 24:464-469.
16. Brooks B.W., Foran C.M., Richards S.M., Weston J., Turner P.K., Stanley J.K., Solomon K.R., Slattery M., La Point T.W. Aquatic ecotoxicology of fluoxetine. Toxicol. Lett. 2003, 142:169-183.
17. Brooks B.W., Huggett D., Boxall A. Pharmaceuticals and personal care products in the environment: research needs for the next decade. Environ. Toxicol. Chem. 2009, 28:2469-2472.
18. Brunet F.G., Crollius H.R., Paris M., Aury J.M., Gibert P. Gene loss and evolutionary rates following whole-genome duplication in teleost fishes. Mol. Biol. Evol. 2006, 23:1808-1816.
19. Calisto V., Esteves V.I. Psychiatric pharmaceuticals in the environment. Chemosphere 2009, 77:1257-1274.
20. Calza P., Pazzi M., Medana C., Baiocchi C., Pelizzetti E. The photocatalyticprocess as a tool to identify metabolitic products formed from dopant substances: the case of buspirone. J. Pharm Biomed Anal. 2004, 35:9-19.
21. Celada P., Bortolozzi A., Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 2013, 27:703-716.
22. Chevaleyre V., Heifets B.D., Kaeser P.S., Sudhof T.C., Castillo P.E. Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron 2007, 54:801-812.
23. Connors K.A., Vallenti T.W., Prosser K.N., Brooks B.W., Onaivi E.S., Gould G.G. Effects of 5-HT1A or endocannabinoid receptor agonists on zebrafish behavior in novel environments. Toxicologist 2011, 120:PS964.
24. Correa-de-Araujo R., Miller G.E., Banthin J.S., Trinh Y. Gender differences in drug use and expenditures in a privately insured population of older adults. J. Women's Health 2005, 14:73-81.
25. Dahlbom S.J., Backström T., Lundstedt-Enkel K., Winberg S. Aggression and monoamines: effects of sex and social rank in zebrafish (Danio rerio). Behav. Brain Res. 2012, 228:333-338.
26. Descarries L., Riad M. Effects of the antidepressant fluoxetine on the subcellular localization of 5-HT1A receptors and SERT. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2012, 1601:2416-2425.
27. Dumuis A., Sebben M., Bockaert J. Pharmacology of 5-hydroxytryptamine 1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture. Mol. Pharmacol. 1988, 33:178-186.
28. Dzieweczynski T.L., Hebert O.L. Fluoxetine alters behavioral consistency of aggression and courtship in male Siamese fighting fish, Betta splendens. Physiol. Behav. 2012, 107:92-97.
29. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 2003, 463:35-53.
30. Gawrecki K.M., Klaine S.J. Behavioral and biochemical responses of hybrid striped bass during and after fluoxetine exposure. Aquat. Toxicol. 2008, 88:207-213.
31. Geary W.A., Toga A.W., Wooten G.F. Quantitative film autoradiography for tritium: methodological considerations. Brain Res. 1985, 337:99-108.
32. Gebauer D.L., Pagnussat N., Piato A.L., Schaefer I.C., Bonan C.D., Lara D.R. Effects of anxiolytics in zebrafish: similarities and differences between benzodiazepines, buspirone and ethanol. Pharmacol. Biochem. Behav. 2011, 99:480-486.
33. 1A receptors in rat brain membranes. Eur. J. Pharmacol. 1995, 288:173-186.
34. Gould G. Aquatic light/dark plus maze novel environment for assessing anxious vs. exploratory behavior in zebrafish (Danio rerio) and other small teleost fish. Zebrafish Neurobehavioral Protocols 2011, 99-108. Springer. A.V. Kalueff, J.M. Cachat (Eds.).
35. 3H] Citalopram binding to serotonin transporter sites in minnow brains. Basic Clin. Pharmacol. Toxicol. 2007, 101:203-210.
36. 2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior. J. Neurochem. 2011, 116:291-303.
37. Gould G.G., Seillier A., Weiss G., Giuffrida A., Burke T.F., Hensler J.G., Rock C., Tristan A., McMahon L.R., Salazar A., O'Connor J.C., Satsangi N., Satsangi R.K., Gu T.T., Treat K., Smolik C., Schultz S.T. Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:260-269.
38. Gould G.G., Burke T.F., Osorio M.D., Smolik C.M., Zhang W.Q., Onaivi E.S., Gu T.T., Desilva M.N., Hensler J.G. Enhanced novelty-induced corticosterone spike and upregulated serotonin 5-HT(1A) and cannabinoid CB(1) receptors in adolescent BTBR mice. Psychoneuroendocrinology 2014, 39:158-169.
39. Guilloux J.P., Mendez-David I., Pehrson A., Guiard B.P., Repérant C., Orvoën S., Gardier A.M., Hen R., Ebert B., Miller S., Sanchez C., David D.J. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology 2013, 73:147-159.
40. Gunnarsson L., Jauhiainen A., Kristiansson E., Nerman O., Larsson D.G.J. Evolutionary conservation of human drug targets in organisms used for environmental risk assessment. Environ. Sci. Technol. 2008, 42:5807-5813.
41. Guo S. Linking genes to brain, behavior and neurological diseases: what can we learn from zebrafish?. Genes Brain Behav. 2004, 3:63-74.
42. Huggett D.B., Cook J.C., Ericson J.F., Williams R.T. A theoretical model for utilizing mammalian pharmacology and safety data to prioritize potential impacts of human pharmaceuticals to fish. Human Ecol. Risk Assess. 2003, 9:1789-1799.
43. Kalueff A.V., Gebhardt M., Stewart A.M., Cachat J.M., Brimmer M., Chawla J.S., Craddock C., Kyzar E.J., Roth A., Landsman S., Gaikwad S., Robinson K., Baatrup E., Tierney K., Shamchuk A., Norton W., Miller N., Nicolson T., Braubach O., Gilman C.P., Pittman J., Rosemberg D.B., Gerlai R., Echevarria D., Lamb E., Neuhauss S.C., Weng W., Bally-Cuif L., Schneider H. Towards a comprehensive catalog of zebrafish behavior 1.0 and beyond. Zebrafish 2013, 10:70-86.
44. Klavarioti M., Mantzavinos D., Kassinos D. Removal of residual pharmaceuticals from aqueous systems by advanced oxidation processes. Environ. Int. 2009, 35:402-417.
45. Klee E.W., Schneider H., Clark K.J., Cousin M.A., Ebbert J.O., Hooten W.M., Karpyak V.M., Warner D.O., Ekker S.C. Zebrafish: a model for the study of addiction genetics. Hum. Genet. 2011, 131:977-1008.
46. Klimek V., Zak-Knapik J., Mackowiak M. Effects of repeated treatment with fluoxetine and citalopram, 5-HT uptake inhibitors, on 5-HT1A and 5-HT2 receptors in the rat brain. J. Psychiatry Neurosci. 1994, 19:63-67.
47. Lam C.S., Rastegar S., Strähle U. Distribution of cannabinoid receptor 1 in the CNS of zebrafish. Neuroscience 2006, 138:83-95.
48. Lesch K.P., Hoh A., Schulte H.M., Osterheider M., Müller T. Long-term fluoxetine treatment decreases 5-HT1A receptor responsivity in obsessive-compulsive disorder. Psychopharmacology (Berl.) 1991, 105:415-420.
49. Li Q., Muma N.A., van de Kar L.D. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J. Pharmacol. Exp. Ther. 1996, 279:1035-1042.
50. Maaswinkel H., Le N., He L., Zhu L., Weng W. Dissociating the effects of habituation, black walls, buspirone and ethanol on anxiety-like behavioral responses in shoaling zebrafish. A 3D approach to social behavior. Pharmacol. Biochem. Behav. 2013, 108:16-27.
51. Maaswinkel H., Zhu L., Weng W. The immediate and the delayed effects of buspirone on zebrafish (Danio rerio) in an open field test: a 3-D approach. Behav. Brain Res. 2012, 234:365-374.
52. Madden J.C., Enoch S.J., Hewitt M., Cronin M.T. Pharmaceuticals in the environment: good practice in predicting acute ecotoxicological effects. Toxicol. Lett. 2009, 185:85-101.
53. Martinovic D., Hogarth W.T., Jones R.E., Sorensen P.W. Exposure to environmental estrogens suppresses the hormones, behavior and competitive reproductive fitness of adult male fathead. Environ. Toxicol. Chem. 2007, 26:271-278.
54. Maurel J.L., Autin J.M., Funes P., Newman-Tancredi A., Colpaert F., Vacher B. High-efficacy 5-HT1A agonists for antidepressant treatment: a renewedopportunity. J. Med. Chem. 2007, 50:5024-5033.
55. Maximino C., da Silva A.W.B., Gouveia A., Herculano A.M. Pharmacological analysis of zebrafish (Danio rerio) scototaxis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:624-631.
56. Maximino C., de Brito T.M., da Silva A.W.B., Herculano A.M., Morato S., Gouveia A. Measuring anxiety in zebrafish: a critical review. Behav. Brain Res. 2010, 214:157-171.
57. Maximino C., Puty B., Benzecry R., Araújo J., Lima M.G., de Jesus Oliveira Batista E., Renata de Matos Oliveira K., Crespo-Lopez M.E., Herculano A.M. Role of serotonin in zebrafish (Danio rerio) anxiety: relationship with serotonin levels and effect of buspirone, WAY 100635, SB 224289, fluoxetine and para-chlorophenylalanine (pCPA) in two behavioral models. Neuropharmacology 2013, 71:83-97.
58. Meccariello R., Chianese R., Cobellis G., Pierantoni R., Fasano S. Cloning of type 1 cannabinoid receptor in Rana esculenta reveals differences between genomic sequence and cDNA. FEBS J. 2007, 274:2909-2920.
59. Mennigen J.A., Stroud P., Zamora J.M., Moon T.W., Trudeau V.L. Pharmaceuticals as neuroendocrine disruptors: lessons learned from fish on Prozac. J. Toxicol. Environ. Health B 2011, 14:387-412.
60. Mueller T., Wullimann M.F. An evolutionary interpretation of teleostean forebrain anatomy. Brain Behav. Evol. 2009, 74:30-42.
61. Naderi N., Haghparast A., Saber-Tehrani A., Rezaii N., Alizadeh A.M., Khani A., Motamedi F. Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice. Pharmacol. Biochem. Behav. 2008, 89:64-75.
62. 3H]-WAY100,635. Br. J. Pharmacol. 2001, 132:518-524.
63. Norton W., Bally-Cuif L. Adult zebrafish as a model organism for behavioural genetics. BMC Neurosci. 2010, 11:90.
64. Norton W.H., Folchert A., Bally-Cuif L. Comparative analysis of serotonin receptor (HTR1A/HTR1B families) and transporter (slc6a4a/b) gene expression in the zebrafish brain. J. Comp. Neurol. 2008, 511:521-542.
65. Norton W.H.J. Toward developmental models of psychiatric disorders in zebrafish. Front. Neural Circuits 2013, 7:79.
66. Oakes K.D., Coors A., Escher B.I., Fenner K., Garric J., Gust M., Knacker T., Kuster A., Kussatz C., Metcalfe C.D., Monteiro S., Moon T.W., Mennigen J.A., Parrott J., Pery A.R.R., Ramil M., Roenefahrt I., Tarazona J.V., Sanchez-Arguello P., Ternes T.A., Boucard T., Trudeau V.L., Van Der Kraak G.J., Servos M.R. Environmental risk assessment for the serotonin re-uptake inhibitor fluoxetine: case study using the European risk assessment framework. Integr. Environ. Assess. Manag. 2010, 6:524-539.
67. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Meozzi P.A., Myers L., Perchuk A., Mora Z., Tagliaferro P.A., Gardner E., Brusco A., Akinshola B.E., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D., Teasenfitz L., Arinami T., Uhl G.R. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS ONE 2008, 3:1640.
68. Onaivi E.S., Ishiguro H., Gong J.P., Patel S., Perchuk A., Meozzi P.A., Myers L., Mora Z., Tagliaferro P., Gardner E., Brusco A., Akinshola B.E., Liu Q.R., Hope B., Iwasaki S., Arinami T., Teasenfitz L., Uhl G.R. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann. N. Y. Acad. Sci. 2006, 1074:514-536.
69. Owens M.J., Morgan W.N., Plott S.J., Nemeroff C.B. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 1997, 283:1305-1322.
70. Painter M.M., Buerkley M.A., Julius M.L., Vajda A.M., Norris D.O., Barber L.B., Furlong E.T., Schultz M.M., Schoenfuss H.L. Antidepressants at environmentally relevant concentrations affect predator avoidance behavior of larval fathead minnows (Pimephales promelas). Environ. Toxicol. Chem. 2009, 28:2677-2684.
71. Panula P., Chen Y.C., Priyadarshini M., Kudo H., Semenova S., Sundvik M., Sallinen V. The comparative neuroanatomy and neurochemistry of zebrafish CNS systems of relevance to human neuropsychiatric diseases. Neurobiol. Dis. 2010, 40:46-57.
72. Papoucheva E., Dumuis A., Sebben M., Richter D.W., Ponimaskin E.G. The 5-hydroxytryptamine(1A) receptor is stably palmitoylated, and acylation is critical for communication of receptor with Gi protein. J. Biol. Chem. 2004, 279:3280-3291.
73. Pehrson A.L., Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr. 2013, 1:1-13.
74. Prather P.L., Martin N.A., Breivogel C.S., Childers S.R. Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol. Pharmacol. 2000, 57:1000-1010.
75. Radjenovic J., Petrovic M., Barcelo D. Complementary mass spectrometry and bioassays for evaluating pharmaceutical-transformation products in treatment of drinking water and wastewater. Trends Anal. Chem. 2009, 28:562-580.
76. Rand-Weaver M., Margiotta-Casaluci L., Patel A., Panter G.H., Owen S.F., Sumpter J.P. The read-across hypothesis and environmental risk assessment of pharmaceuticals. Environ. Sci. Technol. 2013, 47:11384-11395.
77. Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders: a review of progress. J. Clin. Psychiatry 2010, 71:839-854.
78. Ringholm A., Fredriksson R., Poliakova N., Yan Y.L., Postlethwait J.H., Larhammar D., Schiöth H.B. One melanocortin 4 and two melanocortin 5 receptors from zebrafish show remarkable conservation in structure and pharmacology. J. Neurochem. 2002, 82:6-18.
79. Rodriguez-Martin I., de Velasco E.M., Rodriguez R.E. Characterization of cannabinoid-binding sites in zebrafish brain. Neurosci. Lett. 2007, 413:249-254.
80. Rodriguez-Martin I., Herrero-Turrion M.J., Marron Fdez de Velasco E., Gonzalez-Sarmiento R., Rodriguez R.E. Characterization of two duplicate zebrafish Cb2-like cannabinoid receptors. Gene 2007, 389:36-44.
81. Sackerman J., Donegan J.J., Cunningham C.S., Nguyen N.N., Lawless K., Long A., Benno R.H., Gould G.G. Zebrafish behavior in novel environments: effects of acute exposure to anxiolytic compounds and choice of Danio rerio line. Int. J. Comp. Psychol. 2010, 23:43-61.
82. Schiöth H.B., Lagerström M.C., Watanobe H., Jonsson L., Vergoni A.V., Ringholm A., Skarphedinsson J.O., Skuladottir G.V., Klovins J., Fredriksson R. Functional role, structure, and evolution of the melanocortin-4 receptor. Ann. N. Y. Acad. Sci. 2003, 994:74-83.
83. Schultz M.M., Furlong E.T., Kolpin D.W., Werner S.L., Schoenfuss H.L., Barber L.B., Blazer V.S., Norris D.O., Vajda A.M. Antidepressant pharmaceuticals in two U.S. effluent-impacted streams: occurrence and fate in water and sediment, and selective uptake in fish neural tissue. Environ. Sci. Technol. 2010, 44:1918-1925.
84. Severinsen K., Sinning S., Müller H.K., Wiborg O. Characterisation of the zebrafish serotonin transporter functionally links TM10 to the ligand binding site. J. Neurochem. 2008, 105:1794-1805.
85. Soderstrom K. Lessons from nonmammalian species. Curr. Top. Behav. Neurosci. 2009, 1:173-198.
86. Stahl S.M., Lee-Zimmerman C., Cartwright S., Morrissette D.A. Serotonergic drugs for depression and beyond. Curr. Drug Targets 2013, 14:578-585.
87. Stanley J.K., Ramirez A.J., Chambliss C.K., Brooks B.W. Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. Chemosphere 2007, 69:9-16.
88. Ton C., Lin Y., Willett C. Zebrafish as a model for developmental neurotoxicity testing. Birth Defects Res. A: Clin. Mol. Teratol. 2006, 76:553-567.
89. Valenti T.W., Gould G.G., Berninger J.P., Connors K.A., Keele N.B., Prosser K.N., Brooks B.W. Human therapeutic plasma levels of the selective serotonin reuptake inhibitor (SSRI) sertraline decrease serotonin reuptake transporter binding and shelter-seeking behavior in adult male fathead minnows. Environ. Sci. Technol. 2012, 46:2427-2435.
90. Valenti T.W., Perez-Hurtado P., Chambliss C.K., Brooks B.W. Aquatic toxicity of sertraline to Pimephales promelas at environmentally relevant surface water pH. Environ. Toxicol. Chem. 2009, 28:2685-2694.
91. Wang Y., Takai R., Yoshioka H., Shirabe K. Characterization and expression of serotonin transporter genes in zebrafish. Tohoku J. Exp. Med. 2006, 208:267-274.
92. 3H] serotonin in the brain of a telost fish, the Arctic charr (Salvelinus alpinus). J. Exp. Biol. 1996, 199:2429-2435.
93. Wullimann M.F., Rupp B., Reichert H. Neuroanatomy of the Zebrafish Brain: A Topological Atlas 1996, Birkhäuser Basel, Switzerland.